ID   SYUA_HUMAN              Reviewed;         140 AA.
AC   P37840; A8K2A4; Q13701; Q4JHI3; Q6IAU6;
DT   01-OCT-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1994, sequence version 1.
DT   06-JUL-2016, entry version 194.
DE   RecName: Full=Alpha-synuclein;
DE   AltName: Full=Non-A beta component of AD amyloid;
DE   AltName: Full=Non-A4 component of amyloid precursor;
DE            Short=NACP;
GN   Name=SNCA; Synonyms=NACP, PARK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PROTEIN SEQUENCE OF 61-95.
RC   TISSUE=Brain;
RX   PubMed=8248242; DOI=10.1073/pnas.90.23.11282;
RA   Ueda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yoshimoto M.,
RA   Otero D.A., Kondo J., Ihara Y., Saitoh T.;
RT   "Molecular cloning of cDNA encoding an unrecognized component of
RT   amyloid in Alzheimer disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:11282-11286(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2-4 AND 2-5).
RX   PubMed=7601450; DOI=10.1016/0888-7543(95)80208-4;
RA   Campion D., Martin C., Heilig R., Charbonnier F., Moreau V.,
RA   Flaman J.-M., Petit J.-L., Hannequin D., Brice A., Frebourg T.;
RT   "The NACP/synuclein gene: chromosomal assignment and screening for
RT   alterations in Alzheimer disease.";
RL   Genomics 26:254-257(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2-4).
RC   TISSUE=Brain;
RX   PubMed=7802671; DOI=10.1006/bbrc.1994.2816;
RA   Ueda K., Saitoh T., Mori H.;
RT   "Tissue-dependent alternative splicing of mRNA for NACP, the precursor
RT   of non-A beta component of Alzheimer's disease amyloid.";
RL   Biochem. Biophys. Res. Commun. 205:1366-1372(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Xia Y., Silva R.D., Chen X.H., Saitoh T.;
RL   Submitted (JAN-1996) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1 AND 2-4).
RX   PubMed=11156617; DOI=10.1101/gr.165801;
RA   Touchman J.W., Dehejia A., Chiba-Falek O., Cabin D.E., Schwartz J.R.,
RA   Orrison B.M., Polymeropoulos M.H., Nussbaum R.L.;
RT   "Human and mouse alpha-synuclein genes: comparative genomic sequence
RT   analysis and identification of a novel gene regulatory element.";
RL   Genome Res. 11:78-86(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Hu X., Xu Y., Peng X., Yuan J., Qiang B.;
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (JUN-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   PROTEIN SEQUENCE OF 59-96, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Fetal brain cortex;
RA   Lubec G., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [13]
RP   PHOSPHORYLATION AT SER-87 AND SER-129 BY CK1 AND CK2.
RX   PubMed=10617630; DOI=10.1074/jbc.275.1.390;
RA   Okochi M., Walter J., Koyama A., Nakajo S., Baba M., Iwatsubo T.,
RA   Meijer L., Kahle P.J., Haass C.;
RT   "Constitutive phosphorylation of the Parkinson's disease associated
RT   alpha-synuclein.";
RL   J. Biol. Chem. 275:390-397(2000).
RN   [14]
RP   PHOSPHORYLATION BY G-PROTEIN COUPLED RECEPTOR KINASE.
RX   PubMed=10852916; DOI=10.1074/jbc.M003542200;
RA   Pronin A.N., Morris A.J., Surguchov A., Benovic J.L.;
RT   "Synucleins are a novel class of substrates for G protein-coupled
RT   receptor kinases.";
RL   J. Biol. Chem. 275:26515-26522(2000).
RN   [15]
RP   PHOSPHORYLATION AT TYR-125 BY FYN.
RX   PubMed=11162638; DOI=10.1006/bbrc.2000.4253;
RA   Nakamura T., Yamashita H., Takahashi T., Nakamura S.;
RT   "Activated Fyn phosphorylates alpha-synuclein at tyrosine residue
RT   125.";
RL   Biochem. Biophys. Res. Commun. 280:1085-1092(2001).
RN   [16]
RP   INTERACTION WITH PHOSPHOLIPASE D.
RX   PubMed=11821392; DOI=10.1074/jbc.M110414200;
RA   Ahn B.H., Rhim H., Kim S.Y., Sung Y.M., Lee M.Y., Choi J.Y.,
RA   Wolozin B., Chang J.S., Lee Y.H., Kwon T.K., Chung K.C., Yoon S.H.,
RA   Hahn S.J., Kim M.S., Jo Y.H., Min do S.;
RT   "Alpha-synuclein interacts with phospholipase D isozymes and inhibits
RT   pervanadate-induced phospholipase D activation in human embryonic
RT   kidney-293 cells.";
RL   J. Biol. Chem. 277:12334-12342(2002).
RN   [17]
RP   PHOSPHORYLATION AT SER-129.
RX   PubMed=11813001; DOI=10.1038/ncb748;
RA   Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E.,
RA   Goldberg M.S., Shen J., Takio K., Iwatsubo T.;
RT   "alpha-Synuclein is phosphorylated in synucleinopathy lesions.";
RL   Nat. Cell Biol. 4:160-164(2002).
RN   [18]
RP   INTERACTION WITH HISTONES, AND SUBCELLULAR LOCATION.
RX   PubMed=12859192; DOI=10.1021/bi0341152;
RA   Goers J., Manning-Bog A.B., McCormack A.L., Millett I.S., Doniach S.,
RA   Di Monte D.A., Uversky V.N., Fink A.L.;
RT   "Nuclear localization of alpha-synuclein and its interaction with
RT   histones.";
RL   Biochemistry 42:8465-8471(2003).
RN   [19]
RP   ROLE OF THE C-TERMINUS IN FIBRILLOGENESIS.
RX   PubMed=12859200; DOI=10.1021/bi027363r;
RA   Murray I.V., Giasson B.I., Quinn S.M., Koppaka V., Axelsen P.H.,
RA   Ischiropoulos H., Trojanowski J.Q., Lee V.M.;
RT   "Role of alpha-synuclein carboxy-terminus on fibril formation in
RT   vitro.";
RL   Biochemistry 42:8530-8540(2003).
RN   [20]
RP   REVIEW.
RX   PubMed=12558071; DOI=10.2174/1566524033361690;
RA   Alves da Costa C.;
RT   "Recent advances on alpha-synuclein cell biology: functions and
RT   dysfunctions.";
RL   Curr. Mol. Med. 3:17-24(2003).
RN   [21]
RP   MUTAGENESIS OF TYR-39; TYR-125; TYR-133 AND TYR-136, CHARACTERIZATION
RP   OF VARIANT THR-53, AND PHOSPHORYLATION AT TYR-125.
RX   PubMed=12893833; DOI=10.1074/jbc.M213217200;
RA   Takahashi T., Yamashita H., Nagano Y., Nakamura T., Ohmori H.,
RA   Avraham H., Avraham S., Yasuda M., Matsumoto M.;
RT   "Identification and characterization of a novel Pyk2/related adhesion
RT   focal tyrosine kinase-associated protein that inhibits alpha-synuclein
RT   phosphorylation.";
RL   J. Biol. Chem. 278:42225-42233(2003).
RN   [22]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15282274; DOI=10.1523/JNEUROSCI.1594-04.2004;
RA   Fortin D.L., Troyer M.D., Nakamura K., Kubo S., Anthony M.D.,
RA   Edwards R.H.;
RT   "Lipid rafts mediate the synaptic localization of alpha-synuclein.";
RL   J. Neurosci. 24:6715-6723(2004).
RN   [23]
RP   FIBRILS FORMATION, DOMAIN NAC, AND MUTAGENESIS OF 67-GLY--VAL-71;
RP   71-VAL--VAL-82; 76-ALA-VAL-77; VAL-77; ALA-78 AND 85-ALA--PHE-94.
RX   PubMed=19722699; DOI=10.1021/bi900539p;
RA   Waxman E.A., Mazzulli J.R., Giasson B.I.;
RT   "Characterization of hydrophobic residue requirements for alpha-
RT   synuclein fibrillization.";
RL   Biochemistry 48:9427-9436(2009).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   COPPER-BINDING, AND MUTAGENESIS OF ASP-2 AND HIS-50.
RX   PubMed=21319811; DOI=10.1021/bi101912q;
RA   Dudzik C.G., Walter E.D., Millhauser G.L.;
RT   "Coordination features and affinity of the Cu(2)+ site in the alpha-
RT   synuclein protein of Parkinson's disease.";
RL   Biochemistry 50:1771-1777(2011).
RN   [26]
RP   ACETYLATION AT MET-1.
RX   PubMed=22407793; DOI=10.1002/pro.2056;
RA   Trexler A.J., Rhoades E.;
RT   "N-Terminal acetylation is critical for forming alpha-helical oligomer
RT   of alpha-synuclein.";
RL   Protein Sci. 21:601-605(2012).
RN   [27]
RP   STRUCTURE BY NMR IN COMPLEX WITH DETERGENT MICELLES.
RX   PubMed=15615727; DOI=10.1074/jbc.M411805200;
RA   Ulmer T.S., Bax A., Cole N.B., Nussbaum R.L.;
RT   "Structure and dynamics of micelle-bound human alpha-synuclein.";
RL   J. Biol. Chem. 280:9595-9603(2005).
RN   [28]
RP   VARIANT PARK1 THR-53.
RX   PubMed=9197268; DOI=10.1126/science.276.5321.2045;
RA   Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A.,
RA   Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S.,
RA   Chandrasekharappa S., Athanassiadou A., Papapetropoulos T.,
RA   Johnson W.G., Lazzarini A.M., Duvoisin R.C., di Iorio G., Golbe L.I.,
RA   Nussbaum R.L.;
RT   "Mutation in the alpha-synuclein gene identified in families with
RT   Parkinson's disease.";
RL   Science 276:2045-2047(1997).
RN   [29]
RP   VARIANT PARK1 PRO-30.
RX   PubMed=9462735; DOI=10.1038/ng0298-106;
RA   Krueger R., Kuhn W., Mueller T., Woitalla D., Graeber M., Koesel S.,
RA   Przuntek H., Epplen J.T., Schoels L., Riess O.;
RT   "Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's
RT   disease.";
RL   Nat. Genet. 18:106-108(1998).
RN   [30]
RP   VARIANT PARK1/DLB LYS-46.
RX   PubMed=14755719; DOI=10.1002/ana.10795;
RA   Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R.,
RA   Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atares B.,
RA   Llorens V., Gomez Tortosa E., del Ser T., Munoz D.G., de Yebenes J.G.;
RT   "The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy
RT   body dementia.";
RL   Ann. Neurol. 55:164-173(2004).
RN   [31]
RP   CHARACTERIZATION OF VARIANT LYS-46.
RX   PubMed=15498564; DOI=10.1016/j.febslet.2004.09.038;
RA   Choi W., Zibaee S., Jakes R., Serpell L.C., Davletov B.,
RA   Crowther R.A., Goedert M.;
RT   "Mutation E46K increases phospholipid binding and assembly into
RT   filaments of human alpha-synuclein.";
RL   FEBS Lett. 576:363-368(2004).
RN   [32]
RP   VARIANT PARK1 GLN-50.
RX   PubMed=23457019; DOI=10.1002/mds.25421;
RA   Appel-Cresswell S., Vilarino-Guell C., Encarnacion M., Sherman H.,
RA   Yu I., Shah B., Weir D., Thompson C., Szu-Tu C., Trinh J., Aasly J.O.,
RA   Rajput A., Rajput A.H., Jon Stoessl A., Farrer M.J.;
RT   "Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's
RT   disease.";
RL   Mov. Disord. 28:811-813(2013).
RN   [33]
RP   VARIANT PARK1 GLN-50, AND CHARACTERIZATION OF VARIANT PARK1 GLN-50.
RX   PubMed=23427326; DOI=10.1212/WNL.0b013e31828727ba;
RA   Proukakis C., Dudzik C.G., Brier T., MacKay D.S., Cooper J.M.,
RA   Millhauser G.L., Houlden H., Schapira A.H.;
RT   "A novel alpha-synuclein missense mutation in Parkinson disease.";
RL   Neurology 80:1062-1064(2013).
RN   [34]
RP   CHARACTERIZATION OF VARIANT PARK1 GLN-50, SUBCELLULAR LOCATION,
RP   SUBUNIT, AND PHOSPHORYLATION AT SER-129.
RX   PubMed=24936070; DOI=10.1074/jbc.M114.553297;
RA   Khalaf O., Fauvet B., Oueslati A., Dikiy I., Mahul-Mellier A.L.,
RA   Ruggeri F.S., Mbefo M.K., Vercruysse F., Dietler G., Lee S.J.,
RA   Eliezer D., Lashuel H.A.;
RT   "The H50Q mutation enhances alpha-synuclein aggregation, secretion,
RT   and toxicity.";
RL   J. Biol. Chem. 289:21856-21876(2014).
RN   [35]
RP   CHARACTERIZATION OF VARIANTS PARK1 PRO-30; LYS-46; GLN-50 AND THR-53,
RP   MUTAGENESIS OF GLU-35 AND GLU-57, SUBCELLULAR LOCATION, AND SUBUNIT.
RX   PubMed=25561023; DOI=10.1021/cn500332w;
RA   Tsigelny I.F., Sharikov Y., Kouznetsova V.L., Greenberg J.P.,
RA   Wrasidlo W., Overk C., Gonzalez T., Trejo M., Spencer B., Kosberg K.,
RA   Masliah E.;
RT   "Molecular determinants of alpha-synuclein mutants' oligomerization
RT   and membrane interactions.";
RL   ACS Chem. Neurosci. 6:403-416(2015).
CC   -!- FUNCTION: May be involved in the regulation of dopamine release
CC       and transport. Induces fibrillization of microtubule-associated
CC       protein tau. Reduces neuronal responsiveness to various apoptotic
CC       stimuli, leading to a decreased caspase-3 activation.
CC   -!- SUBUNIT: Soluble monomer which can form filamentous aggregates.
CC       Interacts with UCHL1 (By similarity). Interacts with phospholipase
CC       D and histones. {ECO:0000250, ECO:0000269|PubMed:11821392,
CC       ECO:0000269|PubMed:12859192, ECO:0000269|PubMed:15615727,
CC       ECO:0000269|PubMed:24936070, ECO:0000269|PubMed:25561023}.
CC   -!- INTERACTION:
CC       Self; NbExp=32; IntAct=EBI-985879, EBI-985879;
CC       P00519-1:ABL1; NbExp=6; IntAct=EBI-985879, EBI-5278159;
CC       P00519-2:ABL1; NbExp=5; IntAct=EBI-985879, EBI-9254597;
CC       P49841:GSK3B; NbExp=2; IntAct=EBI-985879, EBI-373586;
CC       P08107:HSPA1B; NbExp=7; IntAct=EBI-985879, EBI-629985;
CC       P42858:HTT; NbExp=4; IntAct=EBI-985879, EBI-466029;
CC       Q5S007:LRRK2; NbExp=6; IntAct=EBI-985879, EBI-5323863;
CC       P10636-8:MAPT; NbExp=3; IntAct=EBI-985879, EBI-366233;
CC       P00414:MT-CO3; NbExp=3; IntAct=EBI-985879, EBI-3932264;
CC       Q9UI14:RABAC1; NbExp=4; IntAct=EBI-985879, EBI-712367;
CC       Q01959:SLC6A3; NbExp=3; IntAct=EBI-985879, EBI-6661445;
CC       Q61327:Slc6a3 (xeno); NbExp=5; IntAct=EBI-985879, EBI-7839708;
CC       Q9Y6H5:SNCAIP; NbExp=22; IntAct=EBI-985879, EBI-717182;
CC       P17600:SYN1; NbExp=2; IntAct=EBI-985879, EBI-717274;
CC       Q04917:YWHAH; NbExp=9; IntAct=EBI-9684465, EBI-306940;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol
CC       {ECO:0000269|PubMed:24936070, ECO:0000269|PubMed:25561023}.
CC       Membrane {ECO:0000269|PubMed:24936070}. Nucleus
CC       {ECO:0000269|PubMed:12859192, ECO:0000269|PubMed:24936070}. Cell
CC       junction, synapse {ECO:0000269|PubMed:15282274}. Secreted
CC       {ECO:0000269|PubMed:24936070}. Note=Membrane-bound in dopaminergic
CC       neurons. {ECO:0000269|PubMed:15282274}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1; Synonyms=NACP140;
CC         IsoId=P37840-1; Sequence=Displayed;
CC       Name=2-4; Synonyms=NACP112;
CC         IsoId=P37840-2; Sequence=VSP_006364;
CC       Name=2-5;
CC         IsoId=P37840-3; Sequence=VSP_006363;
CC   -!- TISSUE SPECIFICITY: Expressed principally in brain but is also
CC       expressed in low concentrations in all tissues examined except in
CC       liver. Concentrated in presynaptic nerve terminals.
CC   -!- DOMAIN: The 'non A-beta component of Alzheimer disease amyloid
CC       plaque' domain (NAC domain) is involved in fibrils formation. The
CC       middle hydrophobic region forms the core of the filaments. The C-
CC       terminus may regulate aggregation and determine the diameter of
CC       the filaments. {ECO:0000269|PubMed:19722699}.
CC   -!- PTM: Phosphorylated, predominantly on serine residues.
CC       Phosphorylation by CK1 appears to occur on residues distinct from
CC       the residue phosphorylated by other kinases. Phosphorylation of
CC       Ser-129 is selective and extensive in synucleinopathy lesions. In
CC       vitro, phosphorylation at Ser-129 promoted insoluble fibril
CC       formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway
CC       upon osmotic stress. {ECO:0000269|PubMed:10617630,
CC       ECO:0000269|PubMed:10852916, ECO:0000269|PubMed:11162638,
CC       ECO:0000269|PubMed:11813001, ECO:0000269|PubMed:12893833,
CC       ECO:0000269|PubMed:24936070}.
CC   -!- PTM: Hallmark lesions of neurodegenerative synucleinopathies
CC       contain alpha-synuclein that is modified by nitration of tyrosine
CC       residues and possibly by dityrosine cross-linking to generated
CC       stable oligomers.
CC   -!- PTM: Ubiquitinated. The predominant conjugate is the
CC       diubiquitinated form (By similarity). {ECO:0000250}.
CC   -!- PTM: Acetylation at Met-1 seems to be important for proper folding
CC       and native oligomeric structure. {ECO:0000269|PubMed:22407793}.
CC   -!- DISEASE: Note=Genetic alterations of SNCA resulting in aberrant
CC       polymerization into fibrils, are associated with several
CC       neurodegenerative diseases (synucleinopathies). SNCA fibrillar
CC       aggregates represent the major non A-beta component of Alzheimer
CC       disease amyloid plaque, and a major component of Lewy body
CC       inclusions. They are also found within Lewy body (LB)-like
CC       intraneuronal inclusions, glial inclusions and axonal spheroids in
CC       neurodegeneration with brain iron accumulation type 1.
CC   -!- DISEASE: Parkinson disease 1 (PARK1) [MIM:168601]: A complex
CC       neurodegenerative disorder characterized by bradykinesia, resting
CC       tremor, muscular rigidity and postural instability. Additional
CC       features are characteristic postural abnormalities, dysautonomia,
CC       dystonic cramps, and dementia. The pathology of Parkinson disease
CC       involves the loss of dopaminergic neurons in the substantia nigra
CC       and the presence of Lewy bodies (intraneuronal accumulations of
CC       aggregated proteins), in surviving neurons in various areas of the
CC       brain. The disease is progressive and usually manifests after the
CC       age of 50 years, although early-onset cases (before 50 years) are
CC       known. The majority of the cases are sporadic suggesting a
CC       multifactorial etiology based on environmental and genetic
CC       factors. However, some patients present with a positive family
CC       history for the disease. Familial forms of the disease usually
CC       begin at earlier ages and are associated with atypical clinical
CC       features. {ECO:0000269|PubMed:23427326,
CC       ECO:0000269|PubMed:23457019, ECO:0000269|PubMed:24936070,
CC       ECO:0000269|PubMed:25561023, ECO:0000269|PubMed:9197268,
CC       ECO:0000269|PubMed:9462735}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Parkinson disease 4 (PARK4) [MIM:605543]: A complex
CC       neurodegenerative disorder with manifestations ranging from
CC       typical Parkinson disease to dementia with Lewy bodies. Clinical
CC       features include parkinsonian symptoms (resting tremor, rigidity,
CC       postural instability and bradykinesia), dementia, diffuse Lewy
CC       body pathology, autonomic dysfunction, hallucinations and
CC       paranoia. Note=The disease is caused by mutations affecting the
CC       gene represented in this entry.
CC   -!- DISEASE: Dementia Lewy body (DLB) [MIM:127750]: A
CC       neurodegenerative disorder characterized by mental impairment
CC       leading to dementia, parkinsonism, fluctuating cognitive function,
CC       visual hallucinations, falls, syncopal episodes, and sensitivity
CC       to neuroleptic medication. Brainstem or cortical intraneuronal
CC       accumulations of aggregated proteins (Lewy bodies) are the only
CC       essential pathologic features. Patients may also have hippocampal
CC       and neocortical senile plaques, sometimes in sufficient number to
CC       fulfill the diagnostic criteria for Alzheimer disease.
CC       {ECO:0000269|PubMed:14755719}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the synuclein family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/snca/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L08850; AAA16117.1; -; mRNA.
DR   EMBL; L36674; AAA98493.1; -; mRNA.
DR   EMBL; L36675; AAA98487.1; -; mRNA.
DR   EMBL; D31839; BAA06625.1; -; mRNA.
DR   EMBL; U46901; AAC02114.1; -; Genomic_DNA.
DR   EMBL; U46897; AAC02114.1; JOINED; Genomic_DNA.
DR   EMBL; U46898; AAC02114.1; JOINED; Genomic_DNA.
DR   EMBL; U46899; AAC02114.1; JOINED; Genomic_DNA.
DR   EMBL; AF163864; AAG30302.1; -; Genomic_DNA.
DR   EMBL; AF163864; AAG30303.1; -; Genomic_DNA.
DR   EMBL; AY049786; AAL15443.1; -; mRNA.
DR   EMBL; AK290169; BAF82858.1; -; mRNA.
DR   EMBL; CR457058; CAG33339.1; -; mRNA.
DR   EMBL; DQ088379; AAY88735.1; -; Genomic_DNA.
DR   EMBL; CH471057; EAX06036.1; -; Genomic_DNA.
DR   EMBL; BC013293; AAH13293.1; -; mRNA.
DR   EMBL; BC108275; AAI08276.1; -; mRNA.
DR   CCDS; CCDS3634.1; -. [P37840-1]
DR   CCDS; CCDS43252.1; -. [P37840-2]
DR   PIR; A49669; A49669.
DR   PIR; S56746; S56746.
DR   RefSeq; NP_000336.1; NM_000345.3. [P37840-1]
DR   RefSeq; NP_001139526.1; NM_001146054.1. [P37840-1]
DR   RefSeq; NP_001139527.1; NM_001146055.1. [P37840-1]
DR   RefSeq; NP_009292.1; NM_007308.2. [P37840-2]
DR   RefSeq; XP_011530510.1; XM_011532208.1. [P37840-1]
DR   UniGene; Hs.21374; -.
DR   PDB; 1XQ8; NMR; -; A=1-140.
DR   PDB; 2JN5; NMR; -; A=1-12.
DR   PDB; 2KKW; NMR; -; A=1-140.
DR   PDB; 2M55; NMR; -; B=1-19.
DR   PDB; 2N0A; NMR; -; A/B/C/D/E/F/G/H/I/J=1-140.
DR   PDB; 2X6M; X-ray; 1.62 A; B=132-140.
DR   PDB; 3Q25; X-ray; 1.90 A; A=1-19.
DR   PDB; 3Q26; X-ray; 1.54 A; A=10-42.
DR   PDB; 3Q27; X-ray; 1.30 A; A=32-57.
DR   PDB; 3Q28; X-ray; 1.60 A; A=58-79.
DR   PDB; 3Q29; X-ray; 2.30 A; A/C=1-19.
DR   PDB; 4BXL; NMR; -; C=35-56.
DR   PDB; 4R0U; X-ray; 1.38 A; A=72-78.
DR   PDB; 4R0W; X-ray; 1.50 A; A=70-76.
DR   PDB; 4RIK; X-ray; 1.85 A; A=69-77.
DR   PDB; 4RIL; EM; 1.43 A; A=68-78.
DR   PDB; 4ZNN; EM; 1.41 A; A=47-56.
DR   PDB; 5CRW; X-ray; 1.60 A; B=31-41.
DR   PDBsum; 1XQ8; -.
DR   PDBsum; 2JN5; -.
DR   PDBsum; 2KKW; -.
DR   PDBsum; 2M55; -.
DR   PDBsum; 2N0A; -.
DR   PDBsum; 2X6M; -.
DR   PDBsum; 3Q25; -.
DR   PDBsum; 3Q26; -.
DR   PDBsum; 3Q27; -.
DR   PDBsum; 3Q28; -.
DR   PDBsum; 3Q29; -.
DR   PDBsum; 4BXL; -.
DR   PDBsum; 4R0U; -.
DR   PDBsum; 4R0W; -.
DR   PDBsum; 4RIK; -.
DR   PDBsum; 4RIL; -.
DR   PDBsum; 4ZNN; -.
DR   PDBsum; 5CRW; -.
DR   DisProt; DP00070; -.
DR   ProteinModelPortal; P37840; -.
DR   SMR; P37840; 1-140.
DR   BioGrid; 112506; 466.
DR   DIP; DIP-35354N; -.
DR   IntAct; P37840; 260.
DR   MINT; MINT-2515483; -.
DR   STRING; 9606.ENSP00000338345; -.
DR   BindingDB; P37840; -.
DR   ChEMBL; CHEMBL6152; -.
DR   TCDB; 1.C.77.1.1; the synuclein (synuclein) family.
DR   iPTMnet; P37840; -.
DR   PhosphoSite; P37840; -.
DR   BioMuta; SNCA; -.
DR   DMDM; 586067; -.
DR   EPD; P37840; -.
DR   MaxQB; P37840; -.
DR   PaxDb; P37840; -.
DR   PeptideAtlas; P37840; -.
DR   PRIDE; P37840; -.
DR   TopDownProteomics; P37840-1; -. [P37840-1]
DR   DNASU; 6622; -.
DR   Ensembl; ENST00000336904; ENSP00000338345; ENSG00000145335. [P37840-1]
DR   Ensembl; ENST00000345009; ENSP00000343683; ENSG00000145335. [P37840-2]
DR   Ensembl; ENST00000394986; ENSP00000378437; ENSG00000145335. [P37840-1]
DR   Ensembl; ENST00000394989; ENSP00000378440; ENSG00000145335. [P37840-3]
DR   Ensembl; ENST00000394991; ENSP00000378442; ENSG00000145335. [P37840-1]
DR   Ensembl; ENST00000420646; ENSP00000396241; ENSG00000145335. [P37840-2]
DR   Ensembl; ENST00000505199; ENSP00000421485; ENSG00000145335. [P37840-3]
DR   Ensembl; ENST00000506244; ENSP00000422238; ENSG00000145335. [P37840-1]
DR   Ensembl; ENST00000508895; ENSP00000426955; ENSG00000145335. [P37840-1]
DR   Ensembl; ENST00000618500; ENSP00000484044; ENSG00000145335. [P37840-3]
DR   GeneID; 6622; -.
DR   KEGG; hsa:6622; -.
DR   UCSC; uc003hso.3; human. [P37840-1]
DR   CTD; 6622; -.
DR   GeneCards; SNCA; -.
DR   GeneReviews; SNCA; -.
DR   HGNC; HGNC:11138; SNCA.
DR   HPA; CAB010877; -.
DR   HPA; HPA005459; -.
DR   MalaCards; SNCA; -.
DR   MIM; 127750; phenotype.
DR   MIM; 163890; gene.
DR   MIM; 168600; phenotype.
DR   MIM; 168601; phenotype.
DR   MIM; 605543; phenotype.
DR   neXtProt; NX_P37840; -.
DR   Orphanet; 1648; Dementia with Lewy body.
DR   Orphanet; 171695; Parkinsonian-pyramidal syndrome.
DR   Orphanet; 2828; Young adult-onset Parkinsonism.
DR   PharmGKB; PA35986; -.
DR   eggNOG; ENOG410IWI2; Eukaryota.
DR   eggNOG; ENOG4111TDZ; LUCA.
DR   GeneTree; ENSGT00390000016161; -.
DR   HOGENOM; HOG000008691; -.
DR   HOVERGEN; HBG000481; -.
DR   InParanoid; P37840; -.
DR   KO; K04528; -.
DR   OMA; ILEDMPM; -.
DR   OrthoDB; EOG7034KG; -.
DR   PhylomeDB; P37840; -.
DR   TreeFam; TF332776; -.
DR   Reactome; R-HSA-977225; Amyloid fiber formation.
DR   SignaLink; P37840; -.
DR   SIGNOR; P37840; -.
DR   ChiTaRS; SNCA; human.
DR   EvolutionaryTrace; P37840; -.
DR   GeneWiki; Alpha-synuclein; -.
DR   GenomeRNAi; 6622; -.
DR   PMAP-CutDB; P37840; -.
DR   PRO; PR:P37840; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; P37840; -.
DR   CleanEx; HS_SNCA; -.
DR   ExpressionAtlas; P37840; baseline and differential.
DR   Genevisible; P37840; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0030424; C:axon; IDA:UniProtKB.
DR   GO; GO:0005938; C:cell cortex; IDA:UniProtKB.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0043205; C:fibril; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:Ensembl.
DR   GO; GO:0030426; C:growth cone; IDA:UniProtKB.
DR   GO; GO:0016234; C:inclusion body; IDA:UniProtKB.
DR   GO; GO:0005764; C:lysosome; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0005640; C:nuclear outer membrane; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0098794; C:postsynapse; IEA:GOC.
DR   GO; GO:0005840; C:ribosome; IEA:Ensembl.
DR   GO; GO:0005791; C:rough endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0008021; C:synaptic vesicle; IEA:Ensembl.
DR   GO; GO:0043195; C:terminal bouton; IEA:Ensembl.
DR   GO; GO:0043014; F:alpha-tubulin binding; IPI:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0005507; F:copper ion binding; IDA:UniProtKB.
DR   GO; GO:0043027; F:cysteine-type endopeptidase inhibitor activity involved in apoptotic process; IDA:UniProtKB.
DR   GO; GO:0045502; F:dynein binding; IPI:UniProtKB.
DR   GO; GO:0008198; F:ferrous iron binding; IDA:UniProtKB.
DR   GO; GO:0042393; F:histone binding; IDA:UniProtKB.
DR   GO; GO:0030544; F:Hsp70 protein binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IDA:UniProtKB.
DR   GO; GO:0019894; F:kinesin binding; IPI:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0016491; F:oxidoreductase activity; IDA:UniProtKB.
DR   GO; GO:0005543; F:phospholipid binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0051219; F:phosphoprotein binding; IDA:BHF-UCL.
DR   GO; GO:0048156; F:tau protein binding; IDA:UniProtKB.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0006919; P:activation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:BHF-UCL.
DR   GO; GO:0008344; P:adult locomotory behavior; IEA:Ensembl.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0048148; P:behavioral response to cocaine; IEA:Ensembl.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0071280; P:cellular response to copper ion; IDA:UniProtKB.
DR   GO; GO:0071872; P:cellular response to epinephrine stimulus; TAS:UniProtKB.
DR   GO; GO:0044344; P:cellular response to fibroblast growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IC:ParkinsonsUK-UCL.
DR   GO; GO:0042416; P:dopamine biosynthetic process; TAS:UniProtKB.
DR   GO; GO:0051583; P:dopamine uptake involved in synaptic transmission; TAS:UniProtKB.
DR   GO; GO:0060079; P:excitatory postsynaptic potential; IEA:Ensembl.
DR   GO; GO:0043206; P:extracellular fibril organization; TAS:UniProtKB.
DR   GO; GO:0006631; P:fatty acid metabolic process; IEA:Ensembl.
DR   GO; GO:0060291; P:long-term synaptic potentiation; IEA:Ensembl.
DR   GO; GO:0001774; P:microglial cell activation; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0042775; P:mitochondrial ATP synthesis coupled electron transport; IEA:Ensembl.
DR   GO; GO:0007006; P:mitochondrial membrane organization; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:1904715; P:negative regulation of chaperone-mediated autophagy; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IMP:UniProtKB.
DR   GO; GO:0045963; P:negative regulation of dopamine metabolic process; IEA:Ensembl.
DR   GO; GO:0051585; P:negative regulation of dopamine uptake involved in synaptic transmission; IDA:UniProtKB.
DR   GO; GO:0045920; P:negative regulation of exocytosis; IMP:UniProtKB.
DR   GO; GO:0035067; P:negative regulation of histone acetylation; IDA:UniProtKB.
DR   GO; GO:0031115; P:negative regulation of microtubule polymerization; IDA:BHF-UCL.
DR   GO; GO:1902957; P:negative regulation of mitochondrial electron transport, NADH to ubiquinone; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0032769; P:negative regulation of monooxygenase activity; IDA:BHF-UCL.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:1901215; P:negative regulation of neuron death; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0051622; P:negative regulation of norepinephrine uptake; IDA:UniProtKB.
DR   GO; GO:0010642; P:negative regulation of platelet-derived growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; IEA:Ensembl.
DR   GO; GO:0051612; P:negative regulation of serotonin uptake; IDA:UniProtKB.
DR   GO; GO:0070495; P:negative regulation of thrombin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0032410; P:negative regulation of transporter activity; IDA:UniProtKB.
DR   GO; GO:0006638; P:neutral lipid metabolic process; IEA:Ensembl.
DR   GO; GO:0055114; P:oxidation-reduction process; IDA:UniProtKB.
DR   GO; GO:0006644; P:phospholipid metabolic process; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0045807; P:positive regulation of endocytosis; IDA:UniProtKB.
DR   GO; GO:1903284; P:positive regulation of glutathione peroxidase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1903285; P:positive regulation of hydrogen peroxide catabolic process; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0060732; P:positive regulation of inositol phosphate biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0001956; P:positive regulation of neurotransmitter secretion; IEA:Ensembl.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0071902; P:positive regulation of protein serine/threonine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0001921; P:positive regulation of receptor recycling; IDA:UniProtKB.
DR   GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IDA:UniProtKB.
DR   GO; GO:0031648; P:protein destabilization; IDA:UniProtKB.
DR   GO; GO:0031623; P:receptor internalization; IDA:UniProtKB.
DR   GO; GO:0050812; P:regulation of acyl-CoA biosynthetic process; IEA:Ensembl.
DR   GO; GO:0014059; P:regulation of dopamine secretion; TAS:UniProtKB.
DR   GO; GO:0014048; P:regulation of glutamate secretion; IEA:Ensembl.
DR   GO; GO:0040012; P:regulation of locomotion; IEA:Ensembl.
DR   GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; IEA:Ensembl.
DR   GO; GO:0043030; P:regulation of macrophage activation; IEA:Ensembl.
DR   GO; GO:0010517; P:regulation of phospholipase activity; IDA:UniProtKB.
DR   GO; GO:1903426; P:regulation of reactive oxygen species biosynthetic process; TAS:ParkinsonsUK-UCL.
DR   GO; GO:1903421; P:regulation of synaptic vesicle recycling; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0034341; P:response to interferon-gamma; IDA:UniProtKB.
DR   GO; GO:0070555; P:response to interleukin-1; IDA:UniProtKB.
DR   GO; GO:0010040; P:response to iron(II) ion; IDA:UniProtKB.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IDA:UniProtKB.
DR   GO; GO:0032026; P:response to magnesium ion; IDA:UniProtKB.
DR   GO; GO:0050808; P:synapse organization; IEA:Ensembl.
DR   GO; GO:0048488; P:synaptic vesicle endocytosis; ISS:UniProtKB.
DR   Gene3D; 1.10.287.700; -; 1.
DR   InterPro; IPR001058; Synuclein.
DR   InterPro; IPR002460; Synuclein_alpha.
DR   PANTHER; PTHR13820; PTHR13820; 1.
DR   PANTHER; PTHR13820:SF5; PTHR13820:SF5; 1.
DR   Pfam; PF01387; Synuclein; 1.
DR   PRINTS; PR01212; ASYNUCLEIN.
DR   PRINTS; PR01211; SYNUCLEIN.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Alzheimer disease;
KW   Amyloid; Cell junction; Complete proteome; Copper; Cytoplasm;
KW   Direct protein sequencing; Disease mutation; Membrane; Metal-binding;
KW   Neurodegeneration; Nucleus; Parkinson disease; Parkinsonism;
KW   Phosphoprotein; Reference proteome; Repeat; Secreted; Synapse;
KW   Ubl conjugation.
FT   CHAIN         1    140       Alpha-synuclein.
FT                                /FTId=PRO_0000184022.
FT   REPEAT       20     30       1.
FT   REPEAT       31     41       2.
FT   REPEAT       42     56       3; approximate.
FT   REPEAT       57     67       4.
FT   REGION       20     67       4 X 11 AA tandem repeats of [EGS]-K-T-K-
FT                                [EQ]-[GQ]-V-X(4).
FT   METAL         2      2       Copper. {ECO:0000305}.
FT   METAL        50     50       Copper. {ECO:0000305}.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000269|PubMed:22407793}.
FT   MOD_RES      87     87       Phosphoserine.
FT                                {ECO:0000269|PubMed:10617630}.
FT   MOD_RES     125    125       Phosphotyrosine; by FYN.
FT                                {ECO:0000269|PubMed:11162638,
FT                                ECO:0000269|PubMed:12893833}.
FT   MOD_RES     129    129       Phosphoserine; by BARK1, PLK2, CK2, CK1
FT                                and GRK5. {ECO:0000269|PubMed:10617630,
FT                                ECO:0000269|PubMed:11813001,
FT                                ECO:0000269|PubMed:24936070}.
FT   VAR_SEQ      41     54       Missing (in isoform 2-5).
FT                                {ECO:0000303|PubMed:7601450}.
FT                                /FTId=VSP_006363.
FT   VAR_SEQ     103    130       Missing (in isoform 2-4).
FT                                {ECO:0000303|PubMed:7601450,
FT                                ECO:0000303|PubMed:7802671}.
FT                                /FTId=VSP_006364.
FT   VARIANT      30     30       A -> P (in PARK1; no effect on
FT                                oligomerization; dbSNP:rs104893878).
FT                                {ECO:0000269|PubMed:25561023,
FT                                ECO:0000269|PubMed:9462735}.
FT                                /FTId=VAR_007957.
FT   VARIANT      46     46       E -> K (in PARK1 and DLB; significant
FT                                increase in binding to negatively charged
FT                                phospholipid liposomes; increases
FT                                oligomerization; dbSNP:rs104893875).
FT                                {ECO:0000269|PubMed:14755719,
FT                                ECO:0000269|PubMed:15498564,
FT                                ECO:0000269|PubMed:25561023}.
FT                                /FTId=VAR_022703.
FT   VARIANT      50     50       H -> Q (in PARK1; no effect on protein
FT                                structure; no effect on phosphorylation
FT                                of the protein; no effect on membrane-
FT                                and lipid-binding; increases
FT                                oligomerization; increases fibril
FT                                formation; increases secretion of the
FT                                protein; impairs copper-binding;
FT                                dbSNP:rs201106962).
FT                                {ECO:0000269|PubMed:23427326,
FT                                ECO:0000269|PubMed:23457019,
FT                                ECO:0000269|PubMed:24936070,
FT                                ECO:0000269|PubMed:25561023}.
FT                                /FTId=VAR_070171.
FT   VARIANT      53     53       A -> T (in PARK1; no effect on osmotic
FT                                stress-induced phosphorylation; increases
FT                                oligomerization; dbSNP:rs104893877).
FT                                {ECO:0000269|PubMed:12893833,
FT                                ECO:0000269|PubMed:25561023,
FT                                ECO:0000269|PubMed:9197268}.
FT                                /FTId=VAR_007454.
FT   MUTAGEN       2      2       D->A: Impairs copper-binding.
FT                                {ECO:0000269|PubMed:21319811}.
FT   MUTAGEN      35     35       E->K: No effect on oligomerization.
FT                                {ECO:0000269|PubMed:25561023}.
FT   MUTAGEN      39     39       Y->F: No effect on osmotic stress-induced
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:12893833}.
FT   MUTAGEN      50     50       H->A: Impairs copper-binding.
FT                                {ECO:0000269|PubMed:21319811}.
FT   MUTAGEN      57     57       E->K: Increases oligomerization.
FT                                {ECO:0000269|PubMed:25561023}.
FT   MUTAGEN      67     71       Missing: Reduces polymerization into
FT                                amyloid fibrils.
FT                                {ECO:0000269|PubMed:19722699}.
FT   MUTAGEN      71     82       Missing: Impairs polymerization into
FT                                amyloid fibrils.
FT                                {ECO:0000269|PubMed:19722699}.
FT   MUTAGEN      76     77       Missing: Impairs polymerization into
FT                                amyloid fibrils.
FT                                {ECO:0000269|PubMed:19722699}.
FT   MUTAGEN      76     76       Missing: Does not affect polymerization
FT                                into amyloid fibrils.
FT   MUTAGEN      77     77       Missing: Does not affect polymerization
FT                                into amyloid fibrils.
FT                                {ECO:0000269|PubMed:19722699}.
FT   MUTAGEN      78     78       Missing: Does not affect polymerization
FT                                into amyloid fibrils.
FT                                {ECO:0000269|PubMed:19722699}.
FT   MUTAGEN      85     94       Missing: Reduces polymerization into
FT                                amyloid fibrils.
FT                                {ECO:0000269|PubMed:19722699}.
FT   MUTAGEN     125    125       Y->F: Abolishes osmotic stress-induced
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:12893833}.
FT   MUTAGEN     133    133       Y->F: No effect on osmotic stress-induced
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:12893833}.
FT   MUTAGEN     136    136       Y->F: No effect on osmotic stress-induced
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:12893833}.
FT   HELIX         3     11       {ECO:0000244|PDB:3Q25}.
FT   HELIX        17     19       {ECO:0000244|PDB:2N0A}.
FT   HELIX        21     32       {ECO:0000244|PDB:3Q26}.
FT   HELIX        41     44       {ECO:0000244|PDB:3Q27}.
FT   STRAND       45     47       {ECO:0000244|PDB:4BXL}.
FT   HELIX        52     55       {ECO:0000244|PDB:3Q27}.
FT   HELIX        66     68       {ECO:0000244|PDB:3Q28}.
FT   STRAND       70     78       {ECO:0000244|PDB:2N0A}.
FT   STRAND       80     83       {ECO:0000244|PDB:2N0A}.
FT   STRAND       88     98       {ECO:0000244|PDB:2N0A}.
FT   STRAND      110    113       {ECO:0000244|PDB:1XQ8}.
FT   TURN        120    122       {ECO:0000244|PDB:1XQ8}.
FT   TURN        124    126       {ECO:0000244|PDB:1XQ8}.
FT   TURN        133    136       {ECO:0000244|PDB:2N0A}.
SQ   SEQUENCE   140 AA;  14460 MW;  6BB2F12128931663 CRC64;
     MDVFMKGLSK AKEGVVAAAE KTKQGVAEAA GKTKEGVLYV GSKTKEGVVH GVATVAEKTK
     EQVTNVGGAV VTGVTAVAQK TVEGAGSIAA ATGFVKKDQL GKNEEGAPQE GILEDMPVDP
     DNEAYEMPSE EGYQDYEPEA
//
